Oros push-stick for controlled delivery of active agents

• US 20050089570A1
• Filed: 09/24/2004
• Published: 04/28/2005
• Est. Priority Date: 09/26/2003
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Cruz, Evangeline, Ayer, Atul D., Wong, Alfredo M., Garcia, Carmelita, Hamel, Lawrence G., Ruhlmann, Gregory C., Pollock, Brenda J., Li, Sherry
• Application Number:
  US10/949,180
• Publication Number:
  US 20050089570A1
• Time in Patent Office: Days
• US Class Current: 424/468
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/2086 Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat active cores with a complete drug-free outer coat A61K9/28
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61K 9/4808 characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084
• CPC Class Codes: A61K 9/5084 Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs tablets containing such a mixture A61K9/2077

Abstract

A sustained release dosage form is provided comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides burst release of the pharmaceutically active agent without the use of an immediate release drug coating. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents at a controlled rate. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed.

Claims

1. A sustained release dosage form for delivering a pharmaceutically active agent to a patient in need thereof, comprising:

1) a sustained release component and

2) an immediate release component,

wherein the immediate release component is not an immediate release drug coating.

2. The sustained release dosage form of claim 1, wherein both the sustained release component and the immediate release component are adapted to release as an erodible solid.

3. The sustained release dosage form of claim 1, wherein both the sustained release component and the immediate release component are provided in a single mechanism.

4. The sustained release dosage form of claim 1, wherein the sustained release component provides an ascending rate of release of the active agent.

5. The sustained release dosage form of claim 1, wherein the sustained release component provides zero order rate of release of the active agent.

6. The sustained release dosage form of claim 1, wherein the pharmaceutically active agent has a low solubility in water.

7. The sustained release dosage form of claim 6, wherein the pharmaceutically active agent has a solubility in water of less than 10 mg/ml at 25°

C.

8. The sustained release dosage form of claim 2, wherein the pharmaceutically active agent is present in the erodible solid at a high drug loading.

9. The sustained release dosage form of claim 8, wherein the high drug loading is from about 60% to about 95% by weight.

10. The sustained release dosage form of claim 9, wherein the high drug loading is from about 70% to about 90% by weight.

11. The sustained release dosage form of claim 10, wherein the high drug loading is from about 75% to about 85% by weight.

12. The sustained release dosage form of claim 2, wherein the erodible solid comprises a disintegrant, a binding agent and optionally a surfactant and an osmagent.

13. The sustained release dosage form of claim 12, wherein the pharmaceutically active agent is released in an amount from the immediate release component that is controlled by the relative proportions of the disintegrant, binding agent, osmagent and solubility of the pharmaceutically active agent.

67. A method for providing a sustained release of a pharmaceutically active agent, comprising orally administering to a patient in need thereof a sustained release dosage form according to claim 1.

14. A sustained release dosage form for delivering a nonsteroidal anti-inflammatory agent to a patient in need thereof, comprising:

1) a sustained release component and

2) an immediate release component,

wherein the immediate release component is not an immediate release drug coating.

15. The sustained release dosage form of claim 14, wherein both the sustained release component and the immediate release component are adapted to release as an erodible solid.

16. The sustained release dosage form of claim 14, wherein both the sustained release component and the immediate release component are provided in a single mechanism.

17. The sustained release dosage form of claim 14, wherein the sustained release component provides an ascending rate of release of the nonsteroidal anti-inflammatory agent.

18. The sustained release dosage form of claim 14, wherein the sustained release component provides zero order rate of release of the nonsteroidal anti-inflammatory agent.

19. The sustained release dosage form of claim 14, wherein the nonsteroidal anti-inflammatory agent is an aryl propionic acid or a COX-2 inhibitor.

20. The sustained release dosage form of claim 19, wherein the aryl propionic acid is benoxaprofen, decibuprofen, flurbiprofen, fenoprofen, ibuprofen, indoprofen, ketoprofen, naproxen, naproxol, or oxaprozin, derivatives thereof, or mixtures thereof.

21. The sustained release dosage form of claim 20, wherein the nonsteroidal anti-inflammatory agent is ibuprofen.

22. The sustained release dosage form of claim 15, wherein the erodible solid comprises a disintegrant, a binding agent and optionally a surfactant and an osmagent.

23. The sustained release dosage form of claim 22, wherein the binding agent is a hydroxyalkylcellulose, a hydroxyalkylalkylcellulose, or a polyvinylpyrrolidone.

24. The sustained release dosage form of claim 23, wherein the osmagent is a low molecular weight sugar or a salt.

25. The sustained release dosage form of claim 24, wherein the low molecular weight sugar is sorbitol, mannitol.

26. The sustained release dosage form of claim 22, wherein the osmagent is present in the erodible solid at a weight percent of from about 2% to about 10%.

27. The sustained release dosage form of claim 22, wherein the disintegrant is present in an amount of from about 1% to about 10% by weight.

28. The sustained release dosage form of claim 22, wherein the disintegrant is croscarmellose, crospovidone, or sodium alginate.

29. The sustained release dosage form of claim 15, wherein the erodible solid further comprises a nonionic or ionic surfactant.

30. The sustained release dosage form of claim 29, wherein the nonionic surfactant is a poloxamer, or a fatty acid ester of polyoxyethylene, or mixtures thereof.

31. The sustained release dosage form of claim 29, wherein the surfactant is present in about 0.1% to about 10% percent by weight in the erodible solid.

32. The sustained release dosage form of claim 15, wherein the erodible solid comprises from about 1 to about 10% by weight of a hydroxyalkylcellulose.

33. The sustained release dosage form of claim 32, wherein the erodible solid comprises from about 5% to about 6% hydroxypropylcellulose.

34. The sustained release dosage form of claim 32, wherein the erodible solid comprises from about 2% to about 6% croscarmellose.

35. The sustained release dosage form of claim 32, wherein the erodible solid comprises from about 2% to about 3% sodium lauryl sulfate.

36. The sustained release dosage form of claim 15, wherein the erodible solid comprises from about 1 to about 10% by weight of a polyvinylpyrrolidone.

38. The sustained release dosage form of claim 33, wherein the dosage form provides a burst release of from about 10% to about 50% of the pharmaceutically active agent in the first hour after oral administration of the dosage form.

39. The sustained release dosage form of claim 33, wherein the dosage form provides a burst release of from about 15% to about 30% of the pharmaceutically active agent in the first hour after oral administration of the dosage form.

68. A method for providing a sustained release of a nonsteroidal anti-inflammatory agent, comprising orally administering to a patient in need thereof a sustained release dosage form according to claim 14.

37. A sustained release dosage form comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides a burst release of the pharmaceutically active agent without the presence of a drug coating.

40. The sustained release dosage form of claim 37, wherein the pharmaceutically active agent has a low solubility in water.

41. The sustained release dosage form of claim 40, wherein the pharmaceutically active agent has a solubility in water of less than 10 mg/ml at 25°

C.

42. The sustained release dosage form of claim 40, wherein the pharmaceutically active agent is present in the erodible solid at a high drug loading.

43. The sustained release dosage form of claim 42, wherein the high drug loading is from about 60% to about 95% by weight.

44. The sustained release dosage form of claim 43, wherein the high drug loading is from about 70% to about 90% by weight.

45. The sustained release dosage form of claim 44, wherein the high drug loading is from about 75% to about 85% by weight.

46. The sustained release dosage form of claim 37, wherein the erodible solid comprises a disintegrant, a binding agent and optionally a surfactant and an osmagent.

47. The sustained release dosage form of claim 37, wherein the burst release is controlled by the relative proportions of the disintegrant, binding agent, osmagent and solubility of the pharmaceutically active agent.

54. The sustained release dosage form of claim 46, wherein the erodible solid comprises a disintegrant, a binding agent and optionally a surfactant and an osmagent.

55. The sustained release dosage form of claim 54, wherein the surfactant is a nonionic or ionic surfactant.

56. The sustained release dosage form of claim 55, wherein the ionic surfactant is an alkali salt of a C₈-C₁₈ alkyl sulfate.

57. The sustained release dosage form of claim 55, wherein the nonionic surfactant is a poloxamer, or a fatty acid ester of polyoxyethylene, or mixtures thereof.

69. A method for providing a sustained release of a pharmaceutically active agent, comprising orally administering to a patient in need thereof a sustained release dosage form according to claim 37.

48. A sustained release dosage form comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over prolonged period of time, wherein the rate of release of the pharmaceutically active agent is modulated by the presence of an osmagent in the erodible solid.

70. A method for providing a sustained release of a pharmaceutically active agent, comprising orally administering to a patient in need thereof a sustained release dosage form according to claim 48.

49. A sustained release dosage form comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the rate of release of the pharmaceutically active agent in the first hour is controlled by the amount of osmagent, binding agent and disintegrant present in the erodible solid.

71. A method for providing a sustained release of a pharmaceutically active agent, comprising orally administering to a patient in need thereof a sustained release dosage form according to claim 49.

50. A sustained release dosage form comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the rate of release of the pharmaceutically active agent in the first hour is controlled by the relative rates of hydration of the osmagent, binding agent and disintegrant present in the erodible solid.

51. The sustained release dosage form of claim 50, wherein the pharmaceutically active agent is a nonsteroidal anti-inflammatory agent.

52. The sustained release dosage form of claim 51, wherein the dosage form provides an immediate release of from about 10% to about 50% of the nonsteroidal anti-inflammatory agent in the first hour after oral administration of the dosage form.

53. The sustained release dosage form of claim 52, wherein the dosage form provides an immediate release of from about 15% to about 30% of the nonsteroidal anti-inflammatory agent in the first hour after oral administration of the dosage form.

58. The sustained release dosage form of claim 50, wherein the dosage form provides a zero order release from about 1 hour to about 16 hrs after administration.

59. The sustained release dosage form of claim 58, wherein the dosage form provides a zero order release from about 1 hour to about 10 hrs after administration.

60. The sustained release dosage form of claim 50, wherein the dosage form releases about 90% of the active agent in less than about 12 hrs.

61. The sustained release dosage form of claim 50, wherein the dosage form provides a zero order rate of release for at least a portion of the delivery period.

62. The sustained release dosage form of claim 50, wherein the dosage form provides an ascending rate of release for at least a portion of the delivery period.

72. A method for providing a sustained release of a pharmaceutically active agent, comprising orally administering to a patient in need thereof a sustained release dosage form according to claim 50.

63. A method for providing an effective dose of a nonsteroidal anti-inflammatory agent to a patient in need thereof for an extended period of time, comprising orally administering a sustained release dosage form comprising:

(1) a semipermeable wall defining a cavity and including an exit orifice formed or formable therein;

(2) a drug layer comprising a therapeutically effective amount of a nonsteroidal anti-inflammatory agent contained within the cavity and located adjacent to the exit orifice;

(3) a push displacement layer contained within the cavity and located distal from the exit orifice;

(4) a flow-promoting layer between the inner surface of the semipermeable wall and at least the external surface of the drug layer that is opposite the wall;

wherein the dosage form provides an in vitro rate of release of the nonsteroidal anti-inflammatory agent for up to about 16 hours after being contacted with water in the environment of use.

64. The sustained release dosage form of claim 63, wherein the dosage form further provides an immediate release of the nonsteroidal anti-inflammatory agent without the presence of an immediate release drug coating.

65. The sustained release dosage form of claim 64, wherein the dosage form provides an immediate release of from about 10% to about 50% of the nonsteroidal anti-inflammatory agent in the first hour after oral administration of the dosage form.

66. The sustained release dosage form of claim 65, wherein the dosage form provides an immediate release of from about 15% to about 30% of the nonsteroidal anti-inflammatory agent in the first hour after oral administration of the dosage form.

73. A method for providing a sustained release of a nonsteroidal anti-inflammatory agent, comprising orally administering to a patient in need thereof a sustained release dosage form according to claim 63.